Clinical Trials Directory

Trials / Completed

CompletedNCT01762449

Morbidity and Mortality Follow Up for the Scleroderma Lung Study

Morbidity and Mortality Follow Up of Participants of the Scleroderma Lung Study 1

Status
Completed
Phase
Study type
Observational
Enrollment
158 (actual)
Sponsor
Duke University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary intent of this study is to add to the body of knowledge on scleroderma patients with interstitial lung disease. While lung disease is recognized as the leading cause of death amongst patients with scleroderma, there is not a large body of literature describing the long-term morbidity and mortality rate of these scleroderma patients. For this reason, the investigators are following participants of the Scleroderma Lung Study (NCT00004563) after their participation in that study was concluded. In addition, the investigators will assess if the subjects who received one year of oral cyclophosphamide in the Scleroderma Lung Study experienced progression of their scleroderma-related lung disease following the end of the study.

Detailed description

Retrospective and prospective data will be collected about patients who participated in the Scleroderma Lung Study (SLS). An attempt will be made to include all of the participants of the Scleroderma Lung Study, who were reported as alive at the end of that study. A total of 158 subjects (79 per treatment arm) were randomized on the original Scleroderma Lung Study. Of those, 109 subjects completed the study. A single telephone interview with the participants to assess the occurrence of severe events and a review of the participant's medical records may be conducted. The outcome information will be combined with information collected about all participants in the SLS study. The data being collected includes information on mortality, development of cancers, development of organ failure, and performance status.

Conditions

Interventions

TypeNameDescription
OTHERFollowup survey

Timeline

Start date
2012-07-01
Primary completion
2013-06-01
Completion
2013-08-01
First posted
2013-01-07
Last updated
2014-01-23

Source: ClinicalTrials.gov record NCT01762449. Inclusion in this directory is not an endorsement.